UCFX LIMITED

Comprehensive Financial Health Assessment: UCFX LIMITED

1. Financial Health Score: B+

Explanation: UCFX LIMITED exhibits a robust constitution with excellent liquidity, no external debt pressure, and steadily accumulating equity. However, the heavy reliance on intra-group balances—acting as both a major debtor and creditor—creates a circulatory dependency on the wider corporate family. While the company itself is financially sound, this intercompany "plaque" slightly restricts its standalone financial independence, keeping it just shy of an 'A' grade.

2. Key Vital Signs

• Pulse (Liquidity): Strong and steady. The company’s current ratio sits at a highly healthy 3.18 (£1,044,481 in current assets against £328,264 in current liabilities). The business has more than enough liquid assets to cover its immediate obligations, showing no signs of cash flow asphyxiation.
• Blood Pressure (Solvency): Excellent. Total liabilities (£328,264) are comfortably dwarfed by total assets (£1,044,481), resulting in net assets of £716,217. The financial strain on the business is very low.
• Oxygen Saturation (Cash Reserves): Improving. Cash at bank has grown from £322,202 in 2024 to £381,950 in 2025. Over the last few years, the company has successfully oxygenated its cash reserves, moving from a precarious £31,662 in 2018 to its current highly liquid position.
• Cholesterol Levels (Debtor Concentration): Elevated. Debtors total £662,531, representing over 63% of total assets. More critically, £418,923 of this is "Amounts owed by group undertakings". While common in group structures, this represents a significant blockage in the arteries if the parent or sister companies experience their own financial distress.
• Weight (Capital Structure): Lean. The company carries virtually zero external trade debt (only £138 in trade creditors). The liability side of the balance sheet is made up primarily of other creditors (£271,135) and taxation (£54,453), rather than bank debt or supplier pressure.

3. Diagnosis

Overall Condition: The patient is in robust financial health, operating as a highly liquid, low-debt entity within the IT consultancy sector. However, it functions as an interconnected organ of a larger corporate body rather than a fully independent organism.

Symptoms Analysis: * Healthy Cash Flow & Equity Growth: The P&L reserve has grown from £682,453 to £706,217, indicating the company generated a modest but healthy profit of £23,764 in the 2025 financial year. Combined with a strong cash position, the core business is self-sustaining. * Intercompany Circulatory System: The balance sheet reveals a heavy reliance on the parent company, IPFX International Trustee Company Limited (New Zealand). UCFX is owed £418,923 by group undertakings, while it owes £2,538 to them, and carries £271,135 in "other creditors" (which frequently represents intercompany loans or director financing). This means a vast portion of UCFX's wealth is currently circulating outside its own bank account, trapped in the group's wider financial system. * Lean Operations: With only 1 employee (likely the director, Kevin Plumpton), the business operates with minimal overhead. The complete absence of trade creditors (£138) suggests the company pays its external suppliers almost immediately, which is great for supply chain relationships but could indicate an opportunity to negotiate better payment terms to keep cash in the business even longer.

4. Recommendations

To maintain and improve its financial wellness, UCFX LIMITED should consider the following preventative care and lifestyle adjustments:

1. Cardiovascular Management (Monitor Intercompany Debtors): The £418,923 owed by group undertakings is the largest asset on the balance sheet. While currently healthy, the company must ensure these funds are collectible and that the parent company's financial health remains strong. Establish clear, documented repayment terms or regular clearance schedules for these intercompany balances to prevent a sudden cash flow embolism if the parent company faces distress.
2. Preventative Care (Cash Buffering): The current cash position of £381,950 is excellent for a company of this size. Maintain this emergency fund. Do not allow intercompany transfers to drain this buffer below a level that could cover 6-12 months of operational costs and tax liabilities (currently circa £54,000).
3. Dietary Adjustments (Trade Creditor Utilization): Paying suppliers within days (£138 trade creditors is virtually zero) is an admirable trait, but it means UCFX is not utilizing its supply chain credit facilities. Consider negotiating standard 30, 45, or 60-day payment terms with external suppliers. This acts as a free, short-term cash steroid, keeping capital in the business longer to generate interest or fund operations.
4. Routine Check-ups (Profitability vs. Cash): The profit added to reserves in 2025 was approximately £23,764, yet cash increased by £59,748. This discrepancy is likely due to the repayment of intercompany debtors. In future periods, the director should monitor the relationship between reported profit and actual external cash generation to ensure the "profit" isn't merely trapped in intercompany IOUs.